GlassScriptPhysician profile
Adam W Langley
NPI 1992998736
$3,966.04
in general payments reported to CMS, 2019-2025
39 companies · $781 in 2025
The $781 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $225 · 2021: $577 · 2022: $573 · 2023: $855 · 2024: $730 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,366.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $567.32 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $469.78 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $449.31 | 2021-2025 | |
| Pfizer INC. | $378.74 | 2019-2025 | |
| Lilly USA, LLC | $328.07 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $289.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $222.16 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $176.32 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $159.33 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Coopervision INC. | $91.80 | 2022 | |
| Genentech USA, INC. | $80.13 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $76.17 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $69.25 | 2021 | |
| Astellas Pharma US INC | $61.49 | 2024 | Veozah |
| Tolmar, INC. | $49.42 | 2023-2025 | Jatenzo |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $44.01 | 2020 | |
| Antares Pharma, INC. | $38.52 | 2019 | |
| Shire North American Group INC | $35.64 | 2019 | |
| Organogenesis INC. | $30.10 | 2023 | Puraply |
| Gilead Sciences, INC. | $23.22 | 2019 | |
| Amarin Pharma, INC. | $22.76 | 2020 | |
| Aimmune Therapeutics, INC. | $21.32 | 2025 | Zenpep |
| Pacira Therapeutics, INC. | $20.89 | 2021 | |
| Convatec INC. | $20.84 | 2025 | |
| Viiv Healthcare Company | $20.72 | 2023 | Apretude |
| Optinose US, INC. | $19.69 | 2022 | |
| Depuy Synthes Sales INC. | $19.35 | 2020 | |
| Phadia US INC. | $18.81 | 2025 | Immunocap |
| Novartis Pharmaceuticals Corporation | $18.38 | 2022 | |
| Corcept Therapeutics | $17.03 | 2025 | Korlym |
| Ironwood Pharmaceuticals, INC | $17.01 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.09 | 2020 | |
| Idorsia Pharmaceuticals US INC | $14.91 | 2023 | Quviviq |
| Sanofi Pasteur INC. | $14.73 | 2023 | |
| Tris Pharma INC | $14.41 | 2022 | |
| Biomerieux INC | $13.37 | 2023 | |
| Merck Sharp & Dohme LLC | $12.66 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.17 | 2021 | |
| Allergan, INC. | $11.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Langley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.